High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.

doi:10.1016/j.bjid.2012.08.022

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases - 1 Jan 2000

Vidal José Ernesto, Song Alice Tung Wan, Matos Maria Laura, Bartmann Daniel, Anjos Guilherme Dos, Miranda Érique José Peixoto de, Freitas Ângela Carvalho, Dalben Mirian de Freitas, Santana Claudinei, Segurado Aluísio Cotrim, Barreto Cláudia Cortese, Hernández Adrián Vladimir

Abstract excerpt

OBJECTIVES: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil. METHODS: Prospective cohort study carried out in a tertiary center in Sao Paulo, Brazil. Three-class antiretroviral-experienced patients with confirmed virologic failure began darunavir/ritonavir plus optimized background...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiretroviral Therapy, Highly Active

Share to CD4 Lymphocyte Count

Share to Darunavir

Share to Drug Therapy, Combination

Share to Ritonavir

Share to Sulfonamides

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 23294644
DOI: 10.1016/j.bjid.2012.08.022
PMCID: PMC9427411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.PMID 23294644Read ↗

Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study.Semantic proximity Read ↗

Prevalence of Antiretroviral Drug Resistance Mutations in HIV Seropositive Patients from an Outpatient Clinic of a Large University Hospital from São Paulo, Brazil.Semantic proximity Read ↗

Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil.Semantic proximity Read ↗

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.Semantic proximity Read ↗

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.Semantic proximity Read ↗

Prevalence of ARV resistance mutations and impact of genotyping test in HIV patients with advance disease in São Paulo, Brazil.Semantic proximity Read ↗

HIV-1 genetic diversity and antiretroviral drug resistance among individuals from Roraima state, northern Brazil.Semantic proximity Read ↗

Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIVSemantic proximity Read ↗

High Prevalence of Drug Resistance Mutations Among Patients Failing First-Line Antiretroviral Therapy and Predictors of Virological Response 24 Weeks After Switch to Second-Line Therapy in São Paulo State, Brazil.Semantic proximity Read ↗

The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.